CD163-positive cancer cells are potentially associated with high malignant potential in clear cell renal cell carcinoma
CD163-positive cancer cells are potentially associated with high malignant potential in clear cell renal cell carcinoma
复制标题
DOI：
10.1007/s00795-017-0165-8
复制
发表时间：
2018-03-01
影响因子：
1.8
通讯作者：
Komohara, Yoshihiro
中科院分区：
文献类型：
--
作者：
Ma, Chaoya;Horlad, Hasita;Komohara, Yoshihiro
CD163主要由单核/巨噬细胞表达；然而，最近利用免疫组织化学(IHC)的研究发现，一些癌细胞也表达CD163。本研究通过检测肾透明细胞癌(CcRCC)组织中癌细胞和巨噬细胞CD163的表达，探讨CD163表达与肾透明细胞癌临床预后的关系。对103例肾细胞癌组织进行CD163免疫组织化学染色。CD163阳性的癌细胞占35%(36/103)，但癌细胞的阳性信号明显低于巨噬细胞。CD163阳性的癌细胞在高T分级的患者和女性中优先检测到，并与无进展生存期缩短和总体生存率降低显著相关。值得注意的是，CD163阳性的巨噬细胞在CD163阳性的癌细胞高肿瘤区域被检测到高强度的巨噬细胞浸润。虽然在培养的巨噬细胞中检测到CD163mRNA，但在两种培养的肾癌细胞系中均未检测到CD163mRNA。在癌细胞上检测到阳性信号的详细机制尚不清楚。肿瘤细胞表面CD163抗原的检测可能是判断肾细胞癌患者临床病程的有用指标。
CD163 is preferentially expressed by monocyte/macrophages; however, recent studies using immunohistochemistry (IHC) have reported that some cancer cells also express CD163. In the present IHC study, we investigated CD163 staining of cancer cells and macrophages in clear cell renal cell carcinoma (ccRCC) tissues and determined the relationship between cancer cell CD163 expression and clinical prognosis in patients with ccRCC. IHC for CD163 was performed in ccRCC tissues from 103 patients. CD163-positive cancer cells were detected in 35% of the patients (36/103); however, the positive signals on cancer cells were significantly lower than those on macrophages. CD163-positive cancer cells were preferentially detected in patients with high T classification, and females, and were significantly associated with shortened progression-free survival and a lower overall survival ratio. Notably, a high intensity of CD163-positive macrophage infiltration was detected in the CD163-positive cancer cell-high tumor areas. Although CD163 mRNA was detected in cultured macrophages, no CD163 mRNA was detected in two cultured RCC cell lines. The detailed mechanism by which a positive signal is detected on cancer cells has not been clarified. Detection of the CD163 antigen on cancer cells might be a useful marker for evaluating the clinical course of patients with ccRCC.